Daewoong Files for Domestic Approval of Diabetes Combo Drug Envlozem... Positive Phase 3 Results Expected to Enhance Shareholder Value
Daewoong's subsidiary Daewoong Pharmaceutical has applied for domestic product approval for the type 2 diabetes combination drug 'Envlozem Tab.' (enavogliflozin/gemigliptin) with the Ministry of Food and Drug Safety.
The application is based on a domestic phase 3 clinical trial in patients with inadequate glycemic control on metformin and gemigliptin: the test group (DWP16001 0.3mg) demonstrated non-inferiority in HbA1c reduction vs. control (dapagliflozin 10mg) (-0.92%p vs -0.86%p, 95% CI upper limit 0.06%p < non-inferiority margin 0.35%p).
Additionally, a phase 1 trial confirming pharmacokinetic equivalence between the fixed-dose combination (DWJ1563) and co-administration of individual drugs was submitted.
However, the filing does not guarantee final approval; unexpected results during the review process could lead to changes or abandonment of commercialization plans. Investors should be aware of this risk.
[AI Comprehensive Analysis]This new drug application signifies advancement in Daewoong's diabetes pipeline, potentially offering a competitive combination of an SGLT-2 inhibitor (enavogliflozin) and a DPP-4 inhibitor (gemigliptin). However, approval and actual revenue contribution will take time, and the near-term stock price impact may be limited.
KOSPI Filing Information
Filing: Major Management Matters Related To Investment Decision (Major Management Matters Of Subsidiary) (Application For Domestic Product Approval Of Envlozem)